Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
10/2000
10/19/2000WO2000061146A1 Camptothecin analogs and methods of preparation thereof
10/19/2000WO2000061145A1 Methods of inducing cancer cell death and tumor regression
10/19/2000WO2000061143A1 The use of alpha lipoic acid in the antimetastatic treatment
10/19/2000WO2000061142A1 Method and composition for the treatment of cancer
10/19/2000WO2000061141A2 Methods and compositions for enhancing delivery of therapeutic agents to tissues
10/19/2000WO2000061130A1 Compounds useful in reducing the level of insulin like growth factor-1 (igf-1) in blood
10/19/2000WO2000061124A2 Use off cell membrane penetrating indigoid bisindole derivatives
10/19/2000WO2000061114A1 Fine particles targeting cells and process for producing the same
10/19/2000WO2000061112A2 Solubilized pharmaceutical composition for parenteral administration
10/19/2000WO2000041505A3 Anthranilic acid derivatives
10/19/2000WO2000034780A3 METHODS AND COMPOSITIONS USEFUL FOR TARGETING ACTIVATED VITRONECTIN RECEPTOR αvβ¿3?
10/19/2000WO2000034485A3 Beta-1,3-galactosyltransferase homologs
10/19/2000WO2000034308A3 Protein transduction system and methods of use thereof
10/19/2000WO2000032778A3 Methods and compositions for inhibiting neoplastic cell growth
10/19/2000WO2000032769A3 Mage-10 or mage-8 derived hla-a2.1-binding oligopeptides
10/19/2000WO2000029551A3 Cells, culture methods, and their use in autologous transplantation therapy
10/19/2000WO2000024405A9 Compounds and their therapeutic use with diabetic complications
10/19/2000WO2000012720A8 Elongase genes and uses thereof
10/19/2000WO2000012507A8 Pyrrolobenzodiazepines
10/19/2000WO2000007996A8 Pyrazoles as estrogen receptor modulators
10/19/2000DE19917930A1 Treating estrogen deficiency associated disorders, e.g. menopausal problems, osteoporosis, neoplasia or neurodegenerative disease, using new or known ent-steroids having bone-selective estrogenic activity
10/19/2000DE19917195A1 New peptide derived from the MUC-1 tumor marker, used to induce a cytotoxic T cell response for treatment or prevention of tumors
10/19/2000DE19916837A1 New di- or tetrahydro-benzoazulene derivatives, are integrin inhibitors useful e.g. for treating thrombosis, coronary heart disease, arteriosclerosis, tumors, osteoporosis or rheumatoid arthritis
10/19/2000DE19916719A1 Neue ECE-Inhibitoren, ihre Herstellung und Verwendung New ECE inhibitors, their preparation and use
10/19/2000DE19915057A1 Monoklonale Antikörper gegen das humane Mcm3 Protein, Verfahren zu ihrer Herstellung und ihre Verwendung Monoclonal antibodies to human protein Mcm3, processes for their preparation and their use
10/19/2000CA2760534A1 Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
10/19/2000CA2371223A1 49 human secreted proteins
10/19/2000CA2371172A1 50 human secreted proteins
10/19/2000CA2370767A1 49 human secreted proteins
10/19/2000CA2370523A1 49 human secreted proteins
10/19/2000CA2370267A1 Prodrugs of thrombin inhibitors
10/19/2000CA2370237A1 Methods for the diagnosis and treatment of metastatic prostate tumors
10/19/2000CA2370189A1 48 human secreted proteins
10/19/2000CA2370007A1 Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases
10/19/2000CA2370000A1 Antiproliferative activity of g-righ oligonucleotides and method of using same to bind to nucleolin
10/19/2000CA2369981A1 Therapeutic compounds for inhibiting interleukin-12 signaling and methods for using same
10/19/2000CA2369976A1 The novel antisense-oligos with better stability and antisense effect
10/19/2000CA2369971A1 Aryl or heteroaryl fused imidazole derivatives, their pharmaceutical compositions and agents, and uses thereof
10/19/2000CA2369728A1 Substituted bicyclic heteroaryl compounds as integrin antagonists
10/19/2000CA2369670A1 Indigoid bisindole derivatives
10/19/2000CA2369619A1 Caspase inhibitors and the use thereof
10/19/2000CA2369578A1 Compounds and methods for therapy and diagnosis of lung cancer
10/19/2000CA2369426A1 Radioenhanced cancer treatment using orally administered camptothecin derivatives
10/19/2000CA2369420A1 Treatment of myeloma bone disease with proteasomal and nf-kb activity inhibitors
10/19/2000CA2369413A1 Transmembrane protein expressed in prostate and other cancers
10/19/2000CA2369381A1 Use of tetrahydrocurcuminoids to regulate physiological and pathological events in the skin and mucosa
10/19/2000CA2369303A1 Method and composition for the treatment of cancer
10/19/2000CA2369272A1 Medicinal compositions and their method of preparation
10/19/2000CA2369263A1 Methods and compositions for enhancing delivery of therapeutic agents to tissues
10/19/2000CA2369084A1 Compounds useful in reducing the level of insulin like growth factor-1 (igf-1) in blood
10/19/2000CA2369029A1 Poly(dipeptide) as a drug carrier
10/19/2000CA2368655A1 Dry formulation for transcutaneous immunization
10/19/2000CA2368369A1 Docetaxel in combination with rhumab her2 for the treatment of cancers
10/19/2000CA2368049A1 Integrin receptor ligands
10/19/2000CA2365945A1 Products and methods for treating ptp lar related diseases
10/19/2000CA2365918A1 49 human secreted proteins
10/19/2000CA2365917A1 Bone morphogenic proteins
10/19/2000CA2365913A1 Tumor necrosis factor receptor homologs and nucleic acids encoding the same
10/19/2000CA2365912A1 Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
10/19/2000CA2365910A1 Human proteins and polynucleotides encoding them
10/19/2000CA2365908A1 Reagents and methods for identifying and modulating expression of genes regulated by p21
10/19/2000CA2365905A1 48 human secreted proteins
10/19/2000CA2365623A1 Tyrosine kinase substrate (tks) proteins
10/19/2000CA2365522A1 48 human secreted proteins
10/19/2000CA2364690A1 Novel transduction molecules and methods for using same
10/19/2000CA2364675A1 Methods of inducing cancer cell death and tumor regression
10/19/2000CA2364541A1 Genes associated with diseases of the kidney
10/18/2000EP1044987A2 Gapped 2'-modified oligonucleotides
10/18/2000EP1044977A1 Camptothecin derivatives having antitumor activity
10/18/2000EP1044975A1 Stable crystalline salts of 5-methyltetrahydrofolic acid
10/18/2000EP1044969A2 Processes and intermediates for preparing anti-cancer compounds
10/18/2000EP1044967A2 2-Pyridinylguanidine urokinase inhibitors
10/18/2000EP1044966A1 (Poly)thia-alkyne compounds and their derivatives, compositions containing them and their use
10/18/2000EP1044280A1 SELECTIVE KILLING AND DIAGNOSIS OF p53?+ NEOPLASTIC CELLS
10/18/2000EP1044277A2 Recombinant, active caspases and uses thereof
10/18/2000EP1044266A2 Human signal peptide-containing proteins
10/18/2000EP1044221A1 Novel pectic polysaccharides purified from angelica gigas nakai and purification method and use as immuno-stimulating agent thereof
10/18/2000EP1044218A1 Nucleic acids encoding transferrin receptor-like proteins and products related thereto
10/18/2000EP1044217A2 Sag: sensitive to apoptosis gene
10/18/2000EP1044211A1 36 human secreted proteins
10/18/2000EP1044210A1 Human dendriac and brainiac-3
10/18/2000EP1044199A1 Heterocyclic topoisomerase poisons
10/18/2000EP1044197A2 New piperidinyl-substituted pyridylalkane, alkene and alkine carboxamides
10/18/2000EP1044187A1 N-benzyl-3-indenylacetamides derivatives for treating neoplasia
10/18/2000EP1044018A2 Tumour vaccines for muc1-positive carcinomas
10/18/2000EP1044013A2 Use of a phosphatidylserine/polypeptide conjugate for inducing autoimmunity in the treatment of cancers
10/18/2000EP1044011A1 Pharmaceutical composition having antitumor activity and process for the preparation thereof
10/18/2000EP1044005A1 1,2,4-benzotriazine oxides formulations
10/18/2000EP1044001A1 Integrin receptor antagonists
10/18/2000EP1043998A1 USE OF PYRAZOLO 3,4-b] PYRIDINE AS CYCLIN DEPENDENT KINASE INHIBITORS
10/18/2000EP1043988A1 C-10 carbon-substituted artemisinin-like trioxane compounds having antimalarial, antiproliferative and antitumour activities
10/18/2000EP1043986A2 Mixture and pharmaceutical composition comprising z-4-hydroxytamoxifen and cyclodextrin
10/18/2000EP1043975A1 Magnetically responsive composition
10/18/2000EP1043928A1 Methods and compositions for treating and diagnosing tumors using adenosine receptor activated cells
10/18/2000EP0828507A4 Method for treatment of pain
10/18/2000EP0823901B1 Quinazoline derivative
10/18/2000EP0633886B1 Pharmaceutically active bicyclic-heterocyclic amines
10/18/2000EP0467932B1 Urokinase-type plasminogen activator receptor
10/18/2000CN1270632A APPIL-a novel protein with growth effects
10/18/2000CN1270589A Epothilone derivatives
1 ... 1876 1877 1878 1879 1880 1881 1882 1883 1884 1885 1886 1887 1888 1889 1890 1891 1892 1893 1894 1895 1896 ... 2211